References

Multiple myeloma

10.1038/nrdp.2017.46 · 2017 · External reference

Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project

10.1200/jco.21.02614 · 2022 · External reference

Genomic classification and individualized prognosis in multiple myeloma

10.1200/jco.23.01277 · 2024 · External reference

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

10.1182/bloodadvances.2020002827 · 2020 · External reference

Measurable residual disease and decision-making in multiple myeloma

10.1016/j.hoc.2023.12.009 · 2024 · External reference

Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future

10.1080/10428194.2024.2443550 · 2024 · External reference

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

10.1016/s1470-2045(16)30206-6 · 2016 · External reference

ECOG-ACRIN EAA181: effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation [abstract]

2021 · External reference

Phase III study of daratumumab/rhuph20 (nsc- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapyin patients with multiple myeloma (mm) using minimal residual disease to direct therapy duration (DRAMMATIC study): SWOG s1803

10.1182/blood-2020-142913 · 2020 · External reference

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

10.1038/s41408-024-01156-x · 2024 · External reference

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

10.1182/blood.2021011101 · 2022 · External reference

Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications

10.3389/fonc.2021.801851 · 2021 · External reference

Advances in minimal residual disease monitoring in multiple myeloma

10.1080/10408363.2023.2209652 · 2023 · External reference

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma

10.1182/blood.2024024371 · 2024 · External reference

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

10.1007/s12672-024-00891-8 · 2024 · External reference

Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

10.1038/leu.2017.29 · 2017 · External reference

International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma

10.1200/jco-24-01893 · 2025 · External reference

Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma

10.1038/s41408-025-01232-w · 2025 · External reference

Outcomes of myeloma patients with t(11;14) receiving lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy

10.1182/blood-2018-99-119051 · 2018 · External reference

Impact of autologous transplantation in patients with multiple myeloma with t(11;14): a propensity-score matched analysis

10.1158/1078-0432.ccr-19-0706 · 2019 · External reference

Measurable residual disease–guided therapy in newly diagnosed myeloma

10.1056/nejmoa2505133 · 2025 · External reference

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy

10.1182/blood.2025031952 · 2026 · External reference

Multiple myeloma with t(11;14): unique biology and evolving landscape

2022 · External reference

Natural history of t(11;14) multiple myeloma

10.1038/leu.2017.204 · 2018 · External reference

Multiple myeloma with t(11;14): impact of novel agents on outcome

10.1038/s41408-023-00807-9 · 2023 · External reference

Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma

10.1002/ajh.27023 · 2023 · External reference

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

10.1038/s41408-025-01264-2 · 2025 · External reference

Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 trial

10.1182/blood.v130.suppl_1.905.905 · 2017 · External reference

A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma

10.1158/1078-0432.ccr-21-3430 · 2022 · External reference

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

10.1182/bloodadvances.2018022806 · 2019 · External reference

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

10.1182/blood-2014-01-550020 · 2014 · External reference

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

10.1038/leu.2013.375 · 2014 · External reference

Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial

10.1182/blood.v126.23.191.191 · 2015 · External reference